CN112312970B - 用双特异性抗CD3xMUC16抗体和抗PD-1抗体治疗癌症的方法 - Google Patents

用双特异性抗CD3xMUC16抗体和抗PD-1抗体治疗癌症的方法 Download PDF

Info

Publication number
CN112312970B
CN112312970B CN201980040564.9A CN201980040564A CN112312970B CN 112312970 B CN112312970 B CN 112312970B CN 201980040564 A CN201980040564 A CN 201980040564A CN 112312970 B CN112312970 B CN 112312970B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980040564.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112312970A (zh
Inventor
A·克劳福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN112312970A publication Critical patent/CN112312970A/zh
Application granted granted Critical
Publication of CN112312970B publication Critical patent/CN112312970B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980040564.9A 2018-06-21 2019-06-20 用双特异性抗CD3xMUC16抗体和抗PD-1抗体治疗癌症的方法 Active CN112312970B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21
US62/688,251 2018-06-21
PCT/US2019/038163 WO2019246356A1 (en) 2018-06-21 2019-06-20 Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Publications (2)

Publication Number Publication Date
CN112312970A CN112312970A (zh) 2021-02-02
CN112312970B true CN112312970B (zh) 2025-05-23

Family

ID=67254001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980040564.9A Active CN112312970B (zh) 2018-06-21 2019-06-20 用双特异性抗CD3xMUC16抗体和抗PD-1抗体治疗癌症的方法

Country Status (26)

Country Link
US (1) US11254752B2 (cg-RX-API-DMAC7.html)
EP (2) EP4424712A3 (cg-RX-API-DMAC7.html)
JP (1) JP7403480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102870971B1 (cg-RX-API-DMAC7.html)
CN (1) CN112312970B (cg-RX-API-DMAC7.html)
AU (1) AU2019290170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103887A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003256A1 (cg-RX-API-DMAC7.html)
DK (1) DK3810281T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190088A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984972T3 (cg-RX-API-DMAC7.html)
FI (1) FI3810281T3 (cg-RX-API-DMAC7.html)
HU (1) HUE067985T2 (cg-RX-API-DMAC7.html)
IL (1) IL279251B2 (cg-RX-API-DMAC7.html)
MA (2) MA52962B1 (cg-RX-API-DMAC7.html)
MX (2) MX2020013905A (cg-RX-API-DMAC7.html)
MY (1) MY202134A (cg-RX-API-DMAC7.html)
PH (1) PH12020552115A1 (cg-RX-API-DMAC7.html)
PL (1) PL3810281T3 (cg-RX-API-DMAC7.html)
PT (1) PT3810281T (cg-RX-API-DMAC7.html)
RS (1) RS65886B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012137UA (cg-RX-API-DMAC7.html)
TW (2) TW202504917A (cg-RX-API-DMAC7.html)
WO (1) WO2019246356A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007599B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2023539525A (ja) * 2020-09-02 2023-09-14 ジェンマブ エー/エス 抗体療法
NL2027601B1 (en) * 2021-02-19 2022-09-19 Crm Therapeutics B V Target mediated endocytotic drug delivery
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
CN117015394A (zh) * 2021-03-12 2023-11-07 博际生物医药科技(杭州)有限公司 结合人TGFβ和PD-L1的双功能分子及其应用
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
CN117320700A (zh) * 2021-04-02 2023-12-29 瑞泽恩制药公司 含有抗muc16 x抗cd3双特异性抗体的稳定制剂
JPWO2023033022A1 (cg-RX-API-DMAC7.html) 2021-08-31 2023-03-09
MX2024006187A (es) * 2021-11-24 2024-08-14 Regeneron Pharma Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
MX2024008055A (es) * 2022-01-07 2024-09-06 Regeneron Pharma Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
US20250092135A1 (en) * 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
WO2023176881A1 (ja) * 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197259A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and radiation to treat cancer
WO2018058003A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
MX2019004327A (es) * 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197259A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and radiation to treat cancer
WO2018058003A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer;Crawford et al.;SCIENCE TRANSLATIONAL MEDICINE;1-14 *

Also Published As

Publication number Publication date
FI3810281T3 (fi) 2024-08-14
AU2019290170A1 (en) 2021-01-07
EP3810281B1 (en) 2024-07-24
EP4424712A2 (en) 2024-09-04
IL279251B1 (en) 2025-11-01
IL279251B2 (en) 2026-03-01
CL2020003256A1 (es) 2021-04-30
BR112020025476A2 (pt) 2021-03-16
PL3810281T3 (pl) 2024-11-04
AU2019290170B2 (en) 2026-04-02
MX2020013905A (es) 2021-03-09
MA71708A (fr) 2025-05-30
PT3810281T (pt) 2024-08-02
CN112312970A (zh) 2021-02-02
KR102870971B1 (ko) 2025-10-16
US20190389966A1 (en) 2019-12-26
TW202504917A (zh) 2025-02-01
MY202134A (en) 2024-04-05
EP3810281A1 (en) 2021-04-28
ZA202007599B (en) 2025-02-26
DK3810281T3 (da) 2024-08-19
SG11202012137UA (en) 2021-01-28
RS65886B1 (sr) 2024-09-30
IL279251A (en) 2021-01-31
PH12020552115A1 (en) 2021-08-02
JP7403480B2 (ja) 2023-12-22
EP4424712A3 (en) 2024-11-13
TWI890661B (zh) 2025-07-21
JP2021528423A (ja) 2021-10-21
MX2025008444A (es) 2025-08-01
MA52962B1 (fr) 2024-10-31
HUE067985T2 (hu) 2024-12-28
ES2984972T3 (es) 2024-10-31
US11254752B2 (en) 2022-02-22
WO2019246356A1 (en) 2019-12-26
MA52962A (fr) 2021-04-28
KR20210023981A (ko) 2021-03-04
EA202190088A1 (ru) 2021-03-22
CA3103887A1 (en) 2019-12-26
TW202005985A (zh) 2020-02-01

Similar Documents

Publication Publication Date Title
TWI890661B (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
TWI845626B (zh) 增進治療癌症功效的il-4/il-13途徑抑制劑
US20230312718A1 (en) Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
JP2025509567A (ja) 再発性類上皮肉腫を、二重特異性抗MUC16x 抗CD3抗体単独で、または抗PD-1抗体と組み合わせて治療する方法
JP2026508608A (ja) メラノーマの治療における有効性の増強のためのpd-1阻害剤及びlag-3阻害剤の組み合わせ
CN118475618A (zh) 用双特异性抗CD3xMUC16抗体和抗CTLA-4抗体治疗癌症的方法
HK40114667A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
HK40049064B (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
HK40049064A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
EA046291B1 (ru) Способы лечения злокачественного новообразования биспецифическими антителами против cd3xmuc16 и антителами против pd-1
CN118786145A (zh) 使用双特异性抗MUC16 x抗CD3抗体单独或与抗PD-1抗体组合来治疗复发性卵巢癌的方法
TW202542187A (zh) 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390927

TG01 Patent term adjustment